MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    COMPARISON OF CERVICAL, OCULAR AND MASSETER VESTIBULAR EVOKED MYOGENIC POTENTIALS IN PARKINSON PATIENTS ACCORDING TO CLINICAL SUBGROUPS

    G. Sahbaz, R. Inan, B. Barut (Istanbul, Turkey)

    Objective: The aim of this study is to reveal the differences in the effect of brainstem reflexes between the motor subtypes of PD, akinetic rigid(AR)…
  • 2022 International Congress

    MIBG uptakes in the major salivary glands among Lewy body disease using a semi-automatic quantitative method

    J. Ebina, S. Mizumura, N. Ishii, Y. Kobayashi, M. Shibukawa, J. Nagasawa, M. Yanagihashi, T. Hirayama, K. Kawabe, S. Orimo, O. Kano (Tokyo, Japan)

    Objective: The purpose of the study is to analyze 123I-metaiodobenzhylguanidine (MIBG) uptakes in the submandibular and parotid glands in patient with Lewy body disease (LBD)…
  • 2022 International Congress

    Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease

    M. Dileone, C. Ammann, V. Catanzaro, C. Pagge, R. Piredda, MHG. Monje, I. Navalpotro-Gómez, A. Bergareche, MC. Rodriguez-Oroz, L. Vela, F. Alonso-Frech, MJ. Catalán-Alonso, JA. Molina, N. López-Ariztegui, A. Oliviero, JA. Obeso, G. Foffani (Móstoles, Spain)

    Objective: To investigate the potential of transcranial static magnetic field stimulation (tSMS) as a non-pharmacological, non-invasive, home-based treatment to manage levodopa-induced dyskinesias (LIDs) in Parkinson’s…
  • 2022 International Congress

    Real-world evidence and feasibility of telemedicine for Parkinson’s disease

    G. Rigas, N. Kostikis, N. Tachos, E. Kontogiannis, E. Kostoulas, A. Bousis, S. Konitsiotis, D. Fotiadis (Ioannina, Greece)

    Objective: This work aims to provide real-world evidence for the feasibility of telemedicine in Parkinson’s disease (PD). Adherence data presented pertain to patients paying out…
  • 2022 International Congress

    Changes in gait and mobility measures collected in daily living conditions, in different stages of Parkinson’s disease

    N. Geffen, K. Cohavi, N. Giladi, A. Thaler, R. Alcalay, J. Edgerton, J. Shirvan, J. Cedarbaum, J. Hausdorff, A. Mirelman (Tel Aviv, Israel)

    Objective: To explore mobility measures collected in daily-living conditions in different stages of PD. Background: Gait and mobility impairments are considered a cardinal sign in…
  • 2022 International Congress

    IMPACT OF DEEP BRAIN STIMULATION ELECTRODE POSITION ON GAIT IN PATIENTS WITH PARKINSON’S DISEASE

    J. Bardoň, D. Burďáková, J. Valošek, D. Krahulík, P. Otruba, P. Kaňovský, M. Nevrlý (Olomouc, Czech Republic)

    Objective: The aim of our study is to evaluate the impact of the deep brain stimulation (DBS) electrode position within the subthalamic nucleus on gait…
  • 2022 International Congress

    Plasma biomarkers of disease progression in Parkinson’s disease

    A. Lupini, N. Ashton, A. Pilotto, B. Battaglio, C. Zatti, S. Gipponi, E. Cottini, I. Grossi, A. Salvi, G. de Petro, M. Pizzi, K. Blennow, H. Zetterberg, A. Padovani (Brescia, Italy)

    Objective: To identify the ability of a panel of plasma biomarkers to predict disease progression in PD patients Background: Plasma neurofilament light chain (NfL) has…
  • 2022 International Congress

    Blood neurofilament light chain as a biomarker of Parkinson’s disease

    S. Ganesh, B. Huxford, A. Zirra, C. Edwards, C. Simonet, T. Haque, D. Gallagher, C. Budu, R. Dobson, A. Noyce (London, United Kingdom)

    Objective: The objective of the study was to analyse blood neurofilament light chain (NfL) levels in patients with Parkinson’s disease (PD) and healthy controls (HCs),…
  • 2022 International Congress

    Initial Postmarketing Real World Experience with directSTIM™ DBS System: A Case Series

    W. Polanski, S. Sobottka, V. Coenen, A. Frank, B. Falkenburger (Dresden, Germany)

    Objective: In this study we report the first three cases of a new, CE-marked system for deep brain stimulation. Background: The PMCF study is a…
  • 2022 International Congress

    Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials

    M. Soileau, J. Aldred, A. Antonini, C. Carroll, V. Fung, T. Henriksen, R. Pahwa, D. Santos Garcia, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, A. Spiegel, M. Facheris, J. Zamudio, P. Kukreja, KR. Chaudhuri (Georgetown, USA)

    Objective: To evaluate the effect of foslevodopa/foscarbidopa (LDP/CDP, ABBV-951) on clinical and patient-reported outcomes in advanced Parkinson’s disease (aPD) patients using minimal clinically important difference…
  • « Previous Page
  • 1
  • …
  • 297
  • 298
  • 299
  • 300
  • 301
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley